Skip to main content

Part of UT Health San Antonio

Profiles - UT Health San AntonioProfiles - UT Health Science Center San Antonio

Part of UT Health San Antonio

Menu
  • Home

You are here

  • Profiles Home
  • Faculty Directory
  • Gabriel Magraner, MD
Gabriel Magraner

Contact

210-567-5300

magraner@uthscsa.edu

Programs

  • M.D. in Doctor of Medicine

Departments & Divisions

  • Department of Medicine
  • Division of Gastroenterology

Gabriel Magraner, M.D.

Adjoint Professor

Dr. Gabriel Magraner joined the UTHSC-SA faculty immediately after completing his gastroenterology fellowship in 1993, focusing on patient care and physician training pro-bono all while growing his busy private practice. In time, he earned the title of associate clinical professor. Presently, he serves as staff gastroenterologist at the ALM VA Hospital and is also the onsite director for the gastroenterology fellowship program. He is a fellow of the ACG, AGA, and ASGE and a member of the Alpha Omega Alpha, Phi Kappa Phi, and Phi Beta Kappa honor societies.

  • Professional Background

    Education

    • 1993 - Fellowship - Gastroenterology - UT Health San Antonio, TX
    • 1988 - Internship - Internal Medicine - VA Hospital - Puerto Rico, San Juan
    • 1987 - M.D. - University of Puerto Rico Medical Sciences, San Juan

    Appointments

    • 1994-2018 - Clinical Professor - UT Health San Antonio
    • 1996-2003 - Chairman of Medicine - Northeast Methodist Hospital
  • Instruction & Training

    • 2003, Endoscopic Curiosities, Society of GI Nurses &Assoc.
    • 2002, Colon Cancer Screening, Society of GI Nurses & Assoc.
  • Research & Grants

    1VIT13035 - A multi-centered, randomized, open-labeled, controlled study to investigate the treatment response of Intravenous Injectafer (Ferric Carboxymaltose) vs. Oral Iron to Baseline Hepcidin levels in patients with Iron Deficiency Anemia secondary to Inflammatory Bowel Disease or Gastric Bypass

    P11-282 - A long-term non-interventional registry to assess safety & effectiveness of HUMIRA (Adalimunab) in patients with moderately to severely active Ulcerative Colitis.

    RPC-01-3101 - A phase 3, multi-center, randomized, double-blind, placebo-controlled trial of Oral RPC1063 as induction & maintenance therapy for moderate to severe Ulcerative Colitis.

     

  • Service

    Community

    Medical Missionary, Thirteen trips to the Dominican Republic 2016, Four trips to Lourdes, France 2018

    Board of Directors-Secretary: San Antonio Sports Foundation 1995-2005

map image

UT Health San Antonio

7703 Floyd Curl Drive
San Antonio, TX 78229

210-567-7000

We make lives better ©

We're a part of UT Health San Antonio, provider of comprehensive health,  dental, &  cancer care,  advanced academics,  and  life-saving research.

Web Privacy | Links from websites affiliated with The University of Texas Health Science Center at San Antonio's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.